Click to search

Efficacy and tolerability of fixed-combination acne treatment in adolescents.

Randomized controlled trial
Gold LS. Cutis. 2013.

Abstract

Acne is common among adolescents and can be difficult to manage. Providing an effective treatment method that offers an early onset of action and a favorable tolerability profile may lead to improved adherence, increased satisfaction, and improved clinical outcomes in this patient population. A post hoc analysis was conducted of 1755 adolescents (age range, 12 to < 18 years) with moderate to severe acne who had been enrolled in 2 double-blind, multicenter studies and were randomized to receive either clindamycin phosphate (CP) 1.2%-benzoyl peroxide (BPO) 2.5% gel, CP 1.2%, BPO 2.5%, or vehicle once daily for 12 weeks. Significantly superior reductions in inflammatory, noninflammatory, and total lesion counts were observed in the CP 1.2%-BPO 2.5% gel group versus the other 3 groups (P < or = .002 for all week 12 pairwise comparisons). At week 12, treatment success with CP 1.2%-BPO 2.5% gel was statistically superior to CP 1.2% (P = .004), BPO 2.5% (P = .031), and vehicle (P < .001). Participants observed improvement with CP 1.2%-BPO 2.5% gel treatment as early as week 2, with 31.4% of participants reporting their skin was clear, almost clear, or showed marked improvement. Clindamycin phosphate 1.2%-BPO 2.5% gel was associated with a low incidence of treatment-related adverse events (AEs) and a favorable cutaneous tolerability profile. Clindamycin phosphate 1.2%-BPO 2.5% gel is an effective, safe, and well-tolerated treatment in adolescents with moderate to severe acne. The once-daily regimen, early signs of improvement, favorable cutaneous tolerability profile, and participant satisfaction may lead to increased adherence and improved clinical outcomes.

PMID

23617089 [PubMed - indexed for MEDLINE]
 Citation 4 of 533 Back to results